Toyota Retains Global Auto Sales Crown in 2025 With Record 11.3 Million Vehicles Sold 
Elon Musk’s SpaceX Explores Merger Options With Tesla or xAI, Reports Say 
Puma’s Historic Rivalry With Adidas Enters a New Era as Anta Deal Signals Turnaround Push 
Trump Threatens Aircraft Tariffs as U.S.-Canada Jet Certification Dispute Escalates 
Amazon Stock Dips as Reports Link Company to Potential $50B OpenAI Investment 
Microsoft AI Spending Surge Sparks Investor Jitters Despite Solid Azure Growth 
Woodside Energy Flags Lower 2026 Production Outlook Despite Strong Q4 Revenue Beat 
Google Disrupts Major Residential Proxy Network IPIDEA 
Samsung Electronics Posts Record Q4 2025 Profit as AI Chip Demand Soars 
ASML’s EUV Lithography Machines Power Europe’s Most Valuable Tech Company 
Sandisk Stock Soars After Blowout Earnings and AI-Driven Outlook 
Meta Stock Surges After Q4 2025 Earnings Beat and Strong Q1 2026 Revenue Outlook Despite Higher Capex 
Panama Supreme Court Voids CK Hutchison Port Concessions, Raising Geopolitical and Trade Concerns 
American Airlines Plans Return to Venezuela Flights After U.S. Lifts Ban 
Apple Faces Margin Pressure as Memory Chip Prices Surge Amid AI Boom 
Tesla Q4 Earnings Beat Expectations as Company Accelerates Shift Toward AI and Robotics 
Sanofi, the French pharmaceutical company, will be helping Moderna with the production of COVID-19 vaccines. The move was made in an effort to allow the American pharmaceutical and biotechnology firm to fulfill its orders and meet the demand for its shots.
Sanofi confirms production of Moderna shots
On Monday, April 26, Sanofi said that it has joined hands with the Massachusetts-headquartered biotech firm so it can provide assistance with filling vials and finish the packaging of up to 200 million doses as the demand for the Moderna COVID-19 vaccine is high.
Sanofi will be manufacturing the shots in its facility in Ridgefield, New Jersey. While the French company shared some info about its latest partnership with Moderna, it did not disclose any detail regarding the financial aspect of their deal, as per CNBC.
This is the third contract that Sanofi was able to secure since the start of this year. It previously signed a deal with Pfizer/BioNTech, to help them with supplying more than 125 million doses of coronavirus shots. The company also pledged to complete the filling and packing of Johnson & Johnson vaccines, and it must churn out at least 12 million doses per month.
Sanofi’s contribution in fulfilling Moderna’s COVID-19 vaccine supply will begin in September. While it has many deals to work on, the company is also busy in the development of its own vaccines in partnership with GlaxoSmithKline and another one with Translate Bio.
Sanofi aims to fill the bill for vaccines in the U.S.
The Wall Street Journal reported that based on the info coming from Sanofi’s spokesman, the finished doses of Moderna vaccines are for the U.S. supply where Moderna has an agreement until April 2022.
Meanwhile, Novartis AG and Merck Co. are also helping other makers of the coronavirus vaccines by forming agreements for production. The collaborations among the manufacturers are a collective effort to increase production so every nation in the world can have the doses they need.
Finally, Moderna is planning to distribute a total of 300 million doses of COVID-19 shots in the U.S. by the end of July. The delivery is projected to help President Biden achieve his goal of having the majority of American adults vaccinated by summer.
